![Melissa Abel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Melissa Abel
Public Communications Contact en 89BIO, INC. .
Cargos activos de Melissa Abel
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
89BIO, INC. | Public Communications Contact | - | - |
Historial de carrera de Melissa Abel
Antiguos cargos conocidos de Melissa Abel.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2016 | 01/01/2020 |
Concentric Analgesics, Inc.
![]() Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/2016 | 01/01/2020 |
Smithkline Beecham | Ventas & Marketing | 01/01/1995 | 02/01/1999 |
Formación de Melissa Abel.
Emory University | Masters Business Admin |
The University of Chicago | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Bélgica | 2 |
Operativa
Corporate Officer/Principal | 2 |
Public Communications Contact | 1 |
Sales & Marketing | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Technology Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
89BIO, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Smithkline Beecham | |
Concentric Analgesics, Inc.
![]() Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Technology Services |
Five Prime Therapeutics, Inc.
![]() Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Bolsa de valores
- Insiders
- Melissa Abel
- Experiencia